Hunan Er Kang Pharmaceutical (300267) — Net Asset Quality Index
Hunan Er Kang Pharmaceutical (300267) has a Net Asset Quality Index of 87.4% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.05 Billion minus total liabilities of CN¥634.44 Million yields net assets of CN¥4.42 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Hunan Er Kang Pharmaceutical defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hunan Er Kang Pharmaceutical Net Asset Quality Index Over Time (2008–2024)
This chart shows how Hunan Er Kang Pharmaceutical's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of June 2025, the index stands at 87.4%, representing net assets of CN¥4.42 Billion against total assets of CN¥5.05 Billion CNY. Explore Hunan Er Kang Pharmaceutical cash flow conversion to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Hunan Er Kang Pharmaceutical (2008–2024)
The table below presents the year-by-year Net Asset Quality Index for Hunan Er Kang Pharmaceutical from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hunan Er Kang Pharmaceutical (300267) market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 84.7% | CN¥4.40 Billion | CN¥5.20 Billion | CN¥797.54 Million | ▼ -3.1 pp |
| 2023 | 87.8% | CN¥4.81 Billion | CN¥5.48 Billion | CN¥669.05 Million | ▲ +1.5 pp |
| 2022 | 86.3% | CN¥5.05 Billion | CN¥5.86 Billion | CN¥804.57 Million | ▼ -3.5 pp |
| 2021 | 89.7% | CN¥4.87 Billion | CN¥5.43 Billion | CN¥558.28 Million | ▲ +1.2 pp |
| 2020 | 88.5% | CN¥5.79 Billion | CN¥6.55 Billion | CN¥753.22 Million | ▼ -5.8 pp |
| 2019 | 94.3% | CN¥5.79 Billion | CN¥6.14 Billion | CN¥350.72 Million | ▲ +1.1 pp |
| 2018 | 93.2% | CN¥5.64 Billion | CN¥6.05 Billion | CN¥409.39 Million | ▼ -1.4 pp |
| 2017 | 94.6% | CN¥5.41 Billion | CN¥5.72 Billion | CN¥308.37 Million | ▲ +1.8 pp |
| 2016 | 92.8% | CN¥5.24 Billion | CN¥5.65 Billion | CN¥408.94 Million | ▲ +4.1 pp |
| 2015 | 88.7% | CN¥4.26 Billion | CN¥4.80 Billion | CN¥544.10 Million | ▲ +13.1 pp |
| 2014 | 75.6% | CN¥1.68 Billion | CN¥2.22 Billion | CN¥542.64 Million | ▼ -16.6 pp |
| 2013 | 92.2% | CN¥1.33 Billion | CN¥1.45 Billion | CN¥113.01 Million | ▼ -1.9 pp |
| 2012 | 94.1% | CN¥1.16 Billion | CN¥1.24 Billion | CN¥73.32 Million | ▼ -0.1 pp |
| 2011 | 94.2% | CN¥1.06 Billion | CN¥1.13 Billion | CN¥65.90 Million | ▲ +34.4 pp |
| 2010 | 59.7% | CN¥176.62 Million | CN¥295.77 Million | CN¥119.15 Million | ▲ +0.5 pp |
| 2009 | 59.2% | CN¥110.01 Million | CN¥185.73 Million | CN¥75.72 Million | ▲ +7.7 pp |
| 2008 | 51.5% | CN¥63.01 Million | CN¥122.38 Million | CN¥59.37 Million | — |